Results 231 to 240 of about 364,761 (266)
Some of the next articles are maybe not open access.
Mitochondria in Ischemic Heart Disease
2017A core feature of ischemic heart disease is injury to cardiomyocytes (CMC). Ischemic CMC manifest the molecular mechanisms to undergo the major forms of cell injury and death, namely, oncotic necrosis, necroptosis, apoptosis and unregulated autophagy. Important modulators of ischemic injury are reperfusion and conditioning.
openaire +2 more sources
Platelets and Ischemic Heart Disease
New England Journal of Medicine, 1980It is generally held that impairment of coronary-artery blood flow is a major cause of angina pectoris, myocardial infarction, ventricular arrhythmias, and sudden cardiac death.
openaire +2 more sources
Prostaglandins and ischemic heart disease
The American Journal of Medicine, 1981There is an abundance of information suggesting that prostaglandins are involved in the development and clinical expression of atherosclerosis. Many studies demonstrate a relationship between prostaglandins and the risk factors for peripheral and coronary artery disease.
P D, Hirsh +3 more
openaire +2 more sources
Clofibrate in Ischemic Heart Disease
Annals of Internal Medicine, 1972Excerpt The efficacy of clofibrate treatment for primary and secondary prevention of ischemic heart disease has been a topic of keen interest for some time, mainly because of the lipid-lowering pro...
W T, Friedewald, M, Halperin
openaire +2 more sources
American Heart Journal, 2000
The recent clinical development of drugs for acute ischemic heart disease provides examples of successes and failures in Phase II trials. In the development of thrombolytic therapy for acute myocardial infarction (MI), Phase II trials have generally been designed to identify approaches that improve myocardial reperfusion while minimizing the risk of ...
C B, Granger, A, Skene
openaire +2 more sources
The recent clinical development of drugs for acute ischemic heart disease provides examples of successes and failures in Phase II trials. In the development of thrombolytic therapy for acute myocardial infarction (MI), Phase II trials have generally been designed to identify approaches that improve myocardial reperfusion while minimizing the risk of ...
C B, Granger, A, Skene
openaire +2 more sources
Ischemic heart disease: An overview
The American Journal of Cardiology, 1975The studies on natural history of ischemic heart disease are reviewed and the major predictors of mortality identified. The severity of the coronary atherosclerosis and the status of ventricular function are found to be more important predictors of survival than the clinical presentation.
openaire +2 more sources
[Update in ischemic heart disease].
Revista espanola de cardiologia, 2013This article contains a review of the main developments reported in 2010 concerning the pathophysiology, prevention, prognosis and treatment of ST-segment elevation and non-ST-segment elevation acute coronary syndromes, and of recommendations made by the most recent clinical practice guidelines.
Antonio, Fernández-Ortiz +3 more
openaire +2 more sources
Ischemic Heart Disease in Women
Medical Clinics of North AmericaThis review synthesizes the current understanding of ischemic heart disease in women, briefly discussing differences in risk factors, presentation, and treatment. We have underscored the unique clinical phenotype of IHD in women with a higher prevalence of ischemia with non-obstructive coronary arteries.
Eleonore, Grant, Monika, Sanghavi
openaire +2 more sources